Description
Anviphen Pharmacodynamics
Nootropic, facilitates GABA-mediated transmission of nerve impulses in the central nervous system (direct effect on GABA-ergic receptors). The tranquilizing effect is combined with an activating effect. It also has antiaggregant, antioxidant and some anticonvulsant effects.
It improves the functional state of the brain by normalizing its metabolism and influence on the cerebral blood flow (increases the volumetric and linear velocity, reduces vascular resistance, improves microcirculation, has an anti-aggregant effect). It prolongs the latent period and shortens the duration and severity of nystagmus.
Does not affect choline and adrenoreceptors. Reduces vasovagal symptoms (including headache, feeling of heaviness in the head, sleep disorders, irritability, emotional lability). With a course of treatment increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).
Reduces manifestations of asthenia (improves well-being, increases interest and initiative (motivation of activity)) without sedation or agitation. Helps to reduce feelings of anxiety, tension and restlessness, and normalizes sleep.
In the elderly, it does not cause depression of the central nervous system, muscular relaxant aftereffects are usually absent.
Indications
Asthenic and anxious-neurotic conditions.
Stuttering, tics and enuresis in children from 3 years old.
Attention deficit hyperactivity disorder in children 5-13 years old as part of complex therapy.
Insomnia and night anxiety in the elderly.
Meniere’s disease, dizziness associated with dysfunctions of the vestibular analyzer of various genesis.
Prevention of motion sickness in motion sickness.
As part of the treatment of alcohol withdrawal syndrome to relieve psychopathological and somatovegetative disorders.
Contraindications .
Hypersensitivity, pregnancy, breast-feeding, children under 3 years of age.
With caution:
In erosive-ulcerative lesions of the gastrointestinal tract, liver failure.
Pregnancy and lactation:
Contraindicated.
Dosage and administration
- Inside after a meal.
- Asthenic and anxious-neurotic states:
- Adults: 250-500 mg 3 times a day.
The maximum single dose is 750 mg, for patients over 60 years – 500 mg. The course of treatment is 2-3 weeks. If necessary, the course of treatment may be prolonged to 4-6 weeks. - Children: 3 to 8 years of age – 125 mg up to 3 times a day; 8 to 14 years of age – 250 mg 3 times a day; children over 14 years of age – doses for adults.
Stuttering, tics and enuresis in children:
3 to 8 years old, 125 mg up to 3 times daily; 8 to 14 years old, 250 mg 3 times daily; children over 14 years old, doses for adults. - Attention deficit hyperactivity disorder in children as part of complex therapy:
5 to 8 years old – 100 mg 3 times a day; for children 9 to 13 years old – 250 mg 3 times a day. - Insomnia and nocturnal anxiety in the elderly:
250 to 500 mg 3 times daily.
Meniere’s disease, dizziness associated with vestibular analyzer dysfunctions of various genesis: - During exacerbation in adults, 750 mg 3-4 times daily for 5-7 days, then 250-500 mg 3 times daily for 5-7 days and then 250 mg once daily for 5 days. For treatment of vertigo in dysfunction of the vestibular analyzer of vascular and traumatic genesis – 250 mg 3 times a day for 12 days. Prevention of motion sickness in kinetosis:
250-500 mg once 1 hour before the intended trip or when the first symptoms of motion sickness appear. - Anti-sickness effects of ANVIFEN® increase with dose increase. When pronounced motion sickness symptoms occur (“uncontrollable” vomiting and others) the drug is ineffective.
As a part of complex therapy at alcohol withdrawal syndrome for relieving psychopathological and somatovegetative disorders:
At the beginning of treatment, 250-500 mg 3 times a day in the daytime and 750 mg at night, with gradual reduction of the daily dose to the usual for adults.
